Geoff Meacham

Reshma: seeking better efficacy (more patients <30 mmol) and safety; monitoring depends on trial results.

Reshma endorsed the basket study idea for additional B cell-mediated diseases, teasing upcoming disclosures about Povi's immunology portfolio expansion.

Reshma confirmed interest in an IV pain formulation and highlighted the broader portfolio (suzetragene, 993, Nav1.7) as ensuring they have the best medicine across PO and IV.

Duncan reported 74 payer engagements covering over 210 million lives with conversations going extremely well. On sweat chloride, interest levels are similar US vs Europe but European labeling has fewer liver monitoring requirements driving different switching dynamics.

Duncan confirmed vast majority of newly eligible US patients have started ALYFTREK. Transition pace from TRIKAFTA remains steady. Generated close to $0.5 billion in first 10 months. Strong early European uptake.

Reshma highlighted IgAN involves elevated APRIL and BAFF levels requiring dual inhibition, pove's engineered tissue distribution and binding affinity, strong RUBY-3 clinical data, and superior patient profile with monthly auto-injector.

Reshma acknowledged musculoskeletal potential based on VX-150 data but said acute and neuropathic remain highest priority. Key next milestone is NaV1.7+1.8 combination with synergistic preclinical effect.

Reshma deferred specifics to post-FDA meeting this summer, noting innovation in clinical trial designs but no new details to share.

Stuart explained sweat chloride is not being increasingly adopted in practice despite ALYFTREK data. Switching is driven by the combination of noninferior FEV1, improved sweat chloride, 31 additional mutations, and once-daily dosing.

Stuart confirmed interest across all three target populations: naive patients, those newly eligible via expanded mutations, and transition patients from TRIKAFTA or older modulators.

Reshma deferred specifics to summer after regulatory interactions, noting teams are deep in Phase 2 analysis and engaging KOLs and PIs.

O'Day affirmed diversification remains the objective, both within virology across HIV options and outside virology into oncology and immunology.

Cindy affirmed safety advantage widens in earlier lines where patients are less compromised, including potential in newly diagnosed and even smoldering myeloma. Trial designs underway.

Dan emphasized the most robust pipeline in company history with no major LOEs until 2036 reduces BD urgency versus peers. Spends ~$1B annually on early-stage partnerships across all three therapeutic areas. Proactive and disciplined on later-stage acquisitions. Andy added goal is synergistic derisked late-stage assets that turbocharge top-line growth.

Johanna described broad switching mix across long-acting injectable, branded oral (Descovy), and generic orals. Expects naive patient population to grow with increased awareness. Switches currently dominate over naive starts.

Johanna confirmed broader OUS opportunity versus Descovy which faced generic Truvada competition. Countries not meeting 2030 HIV targets offer partnership opportunities. Reimbursement challenges will take time.

Dietmar described early-stage portfolio strategy focused on optionality across monthly, weekly, and twice-yearly options. Noted CROI data on once-yearly PrEP potential.

Johanna confirmed lenacapavir-based options will erode Biktarvy share as part of total Gilead HIV portfolio strategy, well before the late 2033 LOE.

Chris said the combo aims to beat berobenatide-alone efficacy with good early tolerability; directly addressed the combo-study goals.

Boshoff confirmed 3944 targeting monthly; separate ultra-long-acting prodrug peptide in Phase I targeting potential quarterly dosing; beyond VESPA-4/5/6, planning seven additional studies including cardiovascular metabolic and differentiated combination approaches.

Denton indicated US manufacturing investment and cost efficiency improvements are complementary, not conflicting; working through plans under new government agreement; more color at 2026 guidance.

Bourla cited global minimum tax leveling the playing field, potential further US tax reductions for locally produced goods, but uncertainty causing all companies to be frugal with investments.

Bourla outlined three-year strategy: new launches offset LOEs, EPS growth through margins, pipeline value drives multiple expansion post-2028; Baum emphasized building sustainable franchises.

Aamir Malik gave detailed response on Paxlovid tracking disease burden with higher treatment rates and market share gains versus 2023, plus tailored resource model.

Dave Denton confirmed improved cash flow enables larger BD in 2025; Andrew Baum emphasized focus on breakthrough science, unmet need, and talent acquisition.

Ken Custer cited osteoarthritis knee pain, MASLD/NASH, and chronic lower back pain studies as expansion opportunities for retatrutide.

Anne detailed broad combination therapy efforts: Together PSO (Taltz+Zepbound in psoriasis), Together Amplified PSA and PSO, COMMIT studies in UC and Crohn's (Omvoh+Zepbound), and Phase II brenepatide in asthma. Emphasized unlocking better outcomes for patients with both immune diseases and obesity.

Ilya confirmed dual approach: broad commercial payer access plus expanding direct-to-consumer platform. Both channels important to ensure every patient can access medicines across the portfolio.

Dan confirmed standard GLP-1 GI profile: events frontloaded during titration then declining. No patient characteristics predicted higher adverse events.

Dan confirmed broad ambitions including immunology and neuroscience combinations. Noted Lilly has a second oral incretin behind orforglipron plus multifunctional orals in development.

Dan reframed the question away from single tipping points, describing an accumulation-based model where different payers move at different times. Long-term very bullish on full category reimbursement.

Massacesi separated the two delays: ADEPT-1 is event-driven with slower relapse accrual, ADEPT-2/4 slowed on enrollment quality controls. Answered both.

Cristian said development is already scaled with 7 pivotal studies plus an 8th in head and neck. Strategy is replace where PD-1/PD-L1 plays today, then expand into new indications like MSS CRC and gastric.

Adam denied access bottleneck. Cited 100K+ TRxs surpassing all analogs, Q4 NRx acceleration, and increasing propensity for repeat prescribing. Phase IV switch study coming this quarter.

Chris noted opportunity to address IRA concerns with new administration, highlighting billet and spillover impact as two priority areas.

Chris confirmed emracladine failure creates larger opportunity. Samit noted expanded exploration of dual muscarinic agonism across dementias.

Rob Michael outlined active engagement with administration on Section 301 investigation, direct-to-patient models, and $10B US capital commitment. Jeff Stewart identified leading indicators: overall consumer confidence, middle-income consumer posture toward toxins, and HA filler sentiment (stabilizing but not recovering). TrenibotE launch next year viewed as significant rebound catalyst.

Jeff Stewart supported PBM reform focused on patient affordability. Rob Michael discussed neuroscience as more than psychiatry and explained rationale for obesity entry as sixth growth pillar.

Rob Michael explained accounting rules prevent writing up Tavapadon value despite increased optimism. Emraclidine still pursued in adjunctive schizophrenia and neurodegenerative psychosis.

Jeff Stewart confirmed 2025 modeled as trough with high-single-digit CAGR through 2029 putting revenue north of $7B. Carrie Strom positioned BoNT/E as a category activation tool.